Page 20 - Latest Updates on Trump tariffs

US President Donald Trump announces 100% levies on foreign-made films

US tariffs may script huge setback for Indian films; industry's revenue from US may take 30-40% hit

Stock Market Close Highlights: Sensex, Nifty flat; oil & gas, PSB stocks gain

Stock Market Close Highlights, Sep 29: In the broader market, Nifty MidCap 100 index ended 0.27 per cent higher, while Nifty SmallCap 100 index slipped 0.07 per cent

Chinese firms' low profit margins face new risks from Trump tariffs

The net profit margins of US listed companies in tradeable goods averaged around 12 per cent last year, more than double the 4.9 per cent of their Chinese peers

Tariff uncertainties may spur rise in third-party pharma manufacturing

Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump's 100% tariff threat looms over patented drugs

Best of BS Opinion: GST 2.0 reforms miss underlying core principles

Today's pieces look at the available space for more rate cuts, the sorry state of tribunals, why GST reforms are not really that, and how India can harness its vast non-export MSME sector

Beyond the tariff tears: The 99 per cent opportunity in India's MSME engine

The number of exporting MSMEs, despite a commendable trebling in the last four years, was a meagre 173,350 in May last year

US commerce secy calls for India to open mkts, stop actions harming America

Lutnick said that India must open its markets and take actions that would not 'harm' the US

Sun Pharma hit by US tariff risk, but earnings impact to remain limited

The imposition of a 100 per cent tariff by the US on imports of branded and patented pharmaceutical products starting October 1 may not significantly hurt Indian drug makers, with Sun Pharma being exposed to some headline risk but with limited earnings impact, according to analysts. Among Indian companies, only Sun Pharma has sizeable sales from patented drugs in the US (about 17 per cent of 2024-25 revenue), HSBC Global Investment Research said in a report. The US last week announced the imposition of a 100 per cent tariff on branded or patented drugs entering the United States from October 1, except for pharmaceutical companies building manufacturing plants in the US. The exemption covers projects where construction has started, including sites that have broken ground or are under construction. HSBC said Sun Pharma reported global sales of USD 1.217 billion from patented products in FY25, of which the US market accounted for about USD 1.1 billion (85-90 per cent of global sales),

India a country US 'needs to fix': Trump aide Lutnick amid tariff row

US Commerce Secretary Howard Lutnick escalated criticism of India, urging New Delhi to lower tariffs and rethink Russian oil imports as trade tensions with Washington mount

US tariffs on Indian goods pose major growth risks: Crisil Intelligence

High tariffs imposed by the United States on Indian goods pose a major risk to the country's growth, Crisil Intelligence said in its September report. The tariffs will impact both Indian goods exports and investments, the report added. However, domestic consumption, driven by benign inflation and rate cuts, is expected to support growth, it said. The country's GDP rose to a five-quarter high of 7.8 per cent in the first quarter of fiscal 2025-26, up from 7.4 per cent in the similar quarter in the previous year. Nominal GDP growth, however, slowed to 8.8 per cent from 10.8 per cent during the same period, it added. The report said consumer price index (CPI) inflation is likely to soften to 3.5 per cent in the current fiscal from 4.6 per cent in the previous year. Healthy agricultural growth is expected to keep food inflation under check, though the impact of excess rain was yet to be fully assessed. Lower crude prices and benign global commodity prices are expected to contain non

Brics must defend multilateral trading amid tariff volatility: Jaishankar

External Affairs Minister S Jaishankar has called on BRICS to defend the multilateral trading system amid increasing protectionism and tariff volatility during a meeting of the bloc's foreign ministers here on the sidelines of the UN General Assembly session. When multilateralism is under stress, BRICS has stood firm as a strong voice of reason and constructive change, Jaishankar said in a social media post. In a turbulent world, BRICS must reinforce the message of peacebuilding, dialogue, diplomacy and adherence to international law, he said. As rising protectionism, tariff volatility and non-tariff barriers impact trade flows, BRICS must defend the multilateral trading system, he said. Jaishankar's remarks come weeks after the US slapped 50 per cent tariffs on India, including an additional 25 per cent penalty for its purchase of Russian oil, among the highest in the world. The external affairs minister also called on the bloc to amplify its collective call for a comprehensive .

India may import US corn for ethanol production as trade talks advance

New Delhi seeks removal of penal tariffs on Russian oil purchases as Washington pushes soybean and corn sales, with both sides aiming to seal a trade pact by fall

Indian pharma firms likely to dodge immediate impact of Trump's tariff

Trump's 100% tariffs on branded drugs will spare Indian generics, though analysts see exposure for Sun Pharma, Biocon and Aurobindo, with Jubilant Pharmova set to benefit

Reforms to boost growth, but tariff suspense a risk, says FinMin

Finance ministry warns tariff risks could hit jobs and consumption, while GST rationalisation and reforms are seen as key to sustaining India's growth amid global uncertainties

Trump's new tariffs shake Asian economies still reeling from trade war

On Thursday, Trump announced another round of tariffs, which would go into effect on Oct 1, applying import duties ranging from 25 percent to 100 percent on pharmaceuticals, heavy trucks, etc

Nifty Pharma declines 2% after Donald Trump's 100% tariff on branded drugs

The index tracking domestic pharmaceutical stocks hit a low of 21,390 and then recouped some losses to end at 21,507

EU gears up to open 20 anti-dumping probes against Chinese products

The EU is preparing 20 anti-dumping investigations against China to protect European industries from cheap imports and overcapacity in Chinese manufacturing

Stock market crash today: Trump tariffs, FII selling drag Sensex 733 pts down, Nifty near 24,650

Sensex today | Stock Market crash highlights, Sept 26: In the broader markets, the Nifty MidCap index declined 2.05 per cent and the Nifty SmallCap index eased 2.2 per cent

Trump's tariff threat spotlights US factory plans of pharma firms

Merck & Co., Novo Nordisk A/S and Eli Lilly & Co. are among firms that have started US builds since 2023, with construction sites in Delaware, North Carolina and Texas

Carysil stock price dips 10% on Trump's 50% tariff; gives clarification

Carysil stock, however, pared part of its losses after the company issued a clarification. Around 1:45 PM, the stock was trading 5.12 per cent lower at ₹806.40.